← Back to screener

Niagen Bioscience, Inc. NAGE

Rank #667 · Nasdaq · $0.2B market cap
Audited by Crowe LLP, no going-concern flag in the latest filing.
Score
60.7
P/E
21.7
P/B
6.52
ROE
30.0%
Op. Margin
7.8%
Debt Ratio
78%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★★☆☆☆
Average

P/E 21.7x, P/B 6.52x. Ranks in the top 51% of the universe.

Profitability ★★★☆☆
Good

ROE 30.0%. Ranks in the top 32% of the universe.

Safety ★★★☆☆
Good

Debt ratio 78%. Ranks in the top 32% of the universe.

Growth ★★★★☆
Excellent

Revenue growth of 19.2% year over year. Ranks in the top 20% of the universe.

Growth is the relative strength · Valuation is the relative weakness (relative to this universe).

Financials annual, from SEC 10-K filings

FYRevenueOp. IncomeNet IncomeEquityOp. Margin%Debt%
2011–$-0.0B$-0.0B$0.0B–521
2012–$-0.0B$-0.0B$0.0B–27
2013–$-0.0B$-0.0B$0.0B–197
2014–$-0.0B$-0.0B$0.0B–83
2015–$-0.0B$-0.0B$0.0B–188
2016–$-0.0B$-0.0B$0.0B–238
2017–$-0.0B$-0.0B$0.0B–245
2018$0.0B$-0.0B$-0.0B$0.0B-77.289
2019$0.0B$-0.0B$-0.0B$0.1B-105.128
2020$0.0B$-0.0B$-0.0B$0.0B-67.673
2021$0.1B$-0.0B$-0.0B$0.0B-33.5107
2022$0.1B$-0.0B$-0.0B$0.0B-40.1159
2023$0.1B$-0.0B$-0.0B$0.0B-25.980
2024$0.1B$-0.0B$-0.0B$0.0B-6.792
2025$0.1B$0.0B$0.0B$0.0B7.878

← See the full screener